awh-20240328x8k

0000926617-24-000009.txt : 20240328 0000926617-24-000009.hdr.sgml : 20240328 20240328165032 ACCESSION NUMBER: 0000926617-24-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240328 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 24799972 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 awh-20240328x8k.htm 8-K awh-20240328x8k

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 28, 2024

Aspira Women’s Health Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-34810	33-0595156
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


12117 Bee Caves Road, Building III, Suite 100, Austin, Texas		78738
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (512) 519-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	AWH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

‎

Item 2.02 Results of Operations and Financial Conditions.

On March 28, 2024, Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.	Description
99.1	Press Release issued by Aspira Women’s Health on March 28, 2024
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

‎

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



		ASPIRA WOMEN’S HEALTH INC.

Date: March 28, 2024	By:	/s/ Torsten Hombeck
		Torsten Hombeck
		Chief Financial Officer

EX-99.1 2 awh-20240328xex99_1.htm EX-99.1 2024-03-28 8K Ex 99.1


		Exhibit 99.1

A close up of a logo

Description automatically generated

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year

2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year

Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively

Conference Call and Webcast scheduled for today at 8:30 am ET

AUSTIN, Texas, Mar. 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023.

“We made a great deal of progress in 2023. Not only were we able to cut our cash used in operations in half by aligning spending to business needs, but we simultaneously increased revenues and test volume, implemented enhancements to our commercial organization and achieved important market access milestones,” said Nicole Sandford, Chief Executive Officer of Aspira. “Progress in our innovation program continued to accelerate with the announcement in December of the first ever proteomic blood test to identify endometriomas and the achievement of major milestones in the development of our promising AI-enabled protein and miRNA diagnostic tests for ovarian cancer and endometriosis.”

Sandford continues, “Now, we turn towards 2024 with a strong, talented team and unprecedented momentum for women's health progress at both the Federal and state levels. The hard work of the past two years has positioned us to rise to these opportunities and reach our full potential.”

Fourth Quarter 2023 and Recent Corporate Highlights

Raised $5.5 million in gross proceeds through a registered direct offering with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders.

Received final crosswalk pricing determination from the Centers for Medicare & Medicaid Services (CMS) and approval of the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements.

Announced an exclusive 5-year distribution agreement with Hi-Precision Laboratories, one of the largest medical laboratories in the Philippines.

Presented a poster, entitled: “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” at the AACR Special Conference in Cancer Research. The poster highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests suggesting that using combined approaches could improve the triaging of patients with suspected ovarian cancers.

Presented a late-breaking poster entitled “A Protein Biomarker Test and Artificial Intelligence-Based Algorithm for Ovarian Endometriosis,” at the 71st Annual Scientific Meeting for the Society for Reproductive Investigation. The poster highlighted data from the first non-invasive test for ovarian endometriosis.

Secured reimbursement for Ova1Plus from the California Department of Health Care Services. Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements.

Established a Clinical Advisory Board as an element of the company’s overall mission to develop and distribute high-impact diagnostic tools for gynecologic disease. Each member of the Board is a recognized thought-leader with deep clinical expertise in gynecologic health.

Named Dr. Sandra Milligan as President with direct responsibilities for Research and Development, Operations, Information Technology, and Human Resources.

Fourth Quarter 2023 Financial Highlights

Product revenue was $2.1 million for the three months ended December 31, 2023, compared to $2.1 million for the same period in 2022. The number of OvaSuite tests performed was approximately 5,659 during the three months ended December 31, 2023, flat when compared to the approximately 5,642 OvaSuite tests for the same period in 2022. The average unit price (AUP) increased to $376 for the three months ended December 31, 2023, compared to $369 for the same period in 2022.

Gross profit margin was 57.2% for the three months ended December 31, 2023, compared to 57.6% for the same period in 2022.

Research and development expenses for the three months ended December 31, 2023, increased by $0.1 million, or 7%, compared to the same period in 2022.

Sales and marketing expenses for the three months ended December 31, 2023, decreased by $1.1 million, or 40%, compared to the same period in 2022. This decrease was primarily due to decreased employment-related expenses and travel costs.

General and administrative expenses for the three months ended December 31, 2023, increased by $0.1 million, or 4%, compared to the same period in 2022.

Full Year 2023 Highlights

Product revenue was $9.2 million for the year ended December 31, 2023, compared to $8.0 million for the same period in 2022. The 15% product revenue increase was due to the addition of the Company’s OvaWatch product, and an increase in the average unit price (AUP) per test to $382 for the year ended December 31, 2023, compared to $372 for the same period in 2022.

The number of OvaSuite tests performed increased 12% to approximately 23,990 tests during the year ended December 31, 2023, compared to approximately 21,423 tests for the same period in 2022.

Gross profit margin was 57.5% for the year ended December 31, 2023, compared to 52.8% for the year ended December 31, 2022. The change in gross margin was primarily due to a decrease in variable lab supply and shipping costs compared to the prior year.

Research and development expenses for the year ended December 31, 2023, decreased by $1.9 million, or 32%, compared to the same period in 2022. The decrease was primarily due to a decrease in costs related to the Company’s sponsored research collaboration agreements, a decrease in consulting expenses and a decrease in costs due to the closure of a research and development lab in 2023.

Sales and marketing expenses for the year ended December 31, 2023, decreased by $7.1 million, or 48%, compared to the same period in 2022. This decrease was primarily due to decreased employment-related expenses and travel costs.

General and administrative expenses for the year ended December 31, 2023, decreased by $2.4 million, or 16%, compared to the same period in 2022. This decrease was primarily due to a decrease in employment-related expenses and a decrease in outside legal costs, offset by increased accounting costs.

Balance Sheet Highlights

As of December 31, 2023, Aspira had $2.9 million in cash, including restricted cash. Subsequent to the end of the quarter, Aspira raised $5.5 million in gross proceeds in a registered direct offering and concurrent private placement. Cash used in operating activities was $3.5 million for the three months ended December 31, 2023, compared to $7.1 million in the same period in 2022. Cash used in operating activities for the year ended December 31, 2023, was $15.9 million, a 49% decrease compared to $31.1 million in the same period in 2022.

Conference Call and Webcast Details

Aspira will host a conference call beginning at 8:30 am ET today, March 28, 2024. Conference call and webcast details are as follows:

Time: 8:30 am ET

Toll Free:877-407-4018

International:201-689-8471

Webcast:Click HERE

The webcast will also be available on the Events & Presentations page of the Aspira Women’s Health Investor Relations website. An archive of the webcast replay will be available on the Company’s website for up to 90 days.

About Aspira Women’s Health Inc.

Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.

OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women planned for surgery.

Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.

Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the pipeline development and other statements that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect,

actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor Relations Contact:
Torsten Hombeck, Ph.D.

Chief Financial Officer

Aspira Women’s Health

Investors@aspirawh.com

Aspira Women’s Health Inc.

Condensed Consolidated Balance Sheets

(Amounts in Thousands, Except Share and Par Value Amounts)


	December 31,		December 31,
	2023		2022
Assets	(Unaudited)
Current assets:
Cash and cash equivalents	$	2,597	$	13,306
Accounts receivable, net of reserves of $15 and $9, at September 30, 2023 and December 31, 2022, respectively		1,459		1,245
Prepaid expenses and other current assets		997		1,442
Inventories		227		316
Total current assets		5,280		16,309
Property and equipment, net		165		368
Right-of-use assets		528		282
Restricted cash		258		251
Other assets		31		163
Total assets	$	6,262	$	17,373
Liabilities and Stockholders’ (Deficit) Equity
Current liabilities:
Accounts payable	$	1,261	$	881
Accrued liabilities		2,863		3,402
Current portion of long-term debt		166		403
Short-term debt		670		764
Lease liability		159		77
Total current liabilities		5,119		5,527
Non-current liabilities:
Long-term debt		1,430		2,315
Lease liability		427		272
Warrant liabilities		1,651		2,280
Total liabilities		8,627		10,394
Commitments and contingencies
Stockholders’ (deficit) equity:
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 10,645,049 and 8,306,326 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively		11		8
Additional paid-in capital		515,927		508,584
Accumulated deficit		(518,303)		(501,613)
Total stockholders’ (deficit) equity		(2,365)		6,979
Total liabilities and stockholders’ (deficit) equity	$	6,262	$	17,373

Aspira Women’s Health Inc.

Condensed Consolidated Statements of Operations

(Amounts in Thousands, Except Share and Par Value Amounts)


	Three Months Ended				Year Ended
	December 31,				December 31,
	2023		2022		2023		2022
Revenue:
Product	$	2,130	$	2,080	$	9,153	$	7,970
Genetics		-		73		1		214
Total revenue		2,130		2,153		9,154		8,184
Cost of revenue:
Product		911		926		3,892		3,694
Genetics		-		(13)		-		167
Total cost of revenue		911		913		3,892		3,861
Gross profit		1,219		1,240		5,262		4,323
Operating expenses:
Research and development		1,077		1,002		4,035		5,917
Sales and marketing		1,743		2,888		7,812		14,915
General and administrative		2,534		2,441		12,267		14,629
Total operating expenses		5,354		6,331		24,114		35,461
Loss from operations		(4,135)		(5,091)		(18,852)		(31,138)
Other income (expense), net:
Change in fair value of warrant liabilities		862		468		629		1,704
Interest income, net		2		27		48		17
Forgiveness of DECD loan		-		-		1,000		-
Other income (expense), net		182		5		485		(468)
Total other income (expense), net		1,046		500		2,162		1,253
Net loss	$	(3,089)	$	(4,591)	$	(16,690)	$	(29,885)
Net loss per share - basic and diluted	$	(0.30)	$	(0.55)	$	(1.81)	$	(3.85)
Weighted average common shares used to compute basic and diluted net loss per common share		10,408,132		8,299,729		9,233,306		7,769,109

GRAPHIC 3 awh-20240328xex99_1g001.jpg GRAPHIC begin 644 awh-20240328xex99_1g001.jpg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awh-20240328.xsd EX-101.SCH 00090 - Document - Document and Entity Informationlink:presentationLinklink:calculationLinklink:definitionLink EX-101.LAB 5 awh-20240328_lab.xml EX-101.LAB Document And Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity File Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 awh-20240328_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 28, 2024
Document And Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Mar. 28, 2024
Entity Registrant Name	Aspira Women’s Health Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-34810
Entity Tax Identification Number	33-0595156
Entity Address, Address Line One	12117 Bee Caves Road
Entity Address, Address Line Two	Building III
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78738
City Area Code	512
Local Phone Number	519-0400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AWH
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0000926617
Amendment Flag	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.vermillion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports awh-20240328.xsd awh-20240328_lab.xml awh-20240328_pre.xml awh-20240328x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "awh-20240328x8k.htm": { "nsprefix": "awh", "nsuri": "http://www.vermillion.com/20240328", "dts": { "schema": { "local": [ "awh-20240328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "awh-20240328_lab.xml" ] }, "presentationLink": { "local": [ "awh-20240328_pre.xml" ] }, "inline": { "local": [ "awh-20240328x8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_3_28_2024_To_3_28_2024", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "awh-20240328x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_28_2024_To_3_28_2024", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "awh-20240328x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0000926617-24-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000926617-24-000009-xbrl.zip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

*!7:"I NI&K63B)069]_?$8=5>:C94,*$7V MGU,--D4E0*JIL?\!KHRYMO22%)=&@(*8U-DW^'8$ X';Q#^*Y3!!2S"]CI0* M@CN#G$] G'#-P=,S!18QZ#W\%WZ/+N,$$0%]29FC#B"1-U("CFX%7(_;W@ K M4Y&L%%NKJL"J,>@U\4@]BX50HW)-4<"^"G2JV%D4@^BA2/\.-PGP1N:'&N^< M\%ULNSN/8NF;-TQ]48/!15EZ GKN1OAOCNY+N'B'&YVXXS1WPZ;>.)U1LO3Q M;!+YCV# :D=C:=\O?XU[4$N!^I[>NBU(/'W0$I_NVZK:@(]O2G*0/W">J:7O MR[>[N!T#VY9%Y^XA+7)9*;F?;GX[+G-YQN:"VD Y=L?CDIX;Z S?_RB4:P2\ZI> 5V%*7<01J$?2CAT8T**XXRBY1[<;B M4B: +7"-+T'-HFDV%#&:9(5BAM>POK2*]7@LI@ZB#,$D2S-4C:!?97B%!A]8 M8@$H\@1L1M"E,=ALRNLX?,_9Y8O>*P)6 D8ETE@88*=#6,7-S!" MY16 LA8CP T1)_72-J)F,NX;+NX8WK%?B'];O7JOLPH+-]E)?HI [%@("$4W M7=4[X_".(';5> \"?O?)J)UA,UAM$F,(& H+F(>8?,V#'X#+$A<.>,B Q&/X M.7^*#_YF!-E/1G6FX\-&JPE6ZH@L5K/ MWIF^S/7].,)D"Y M0+; L]@"IWE4WL?L$W'C!5F">P$=G8, #TIC.YY6G9U_9Q42HW>M2DA.,YTP/ M_ROP@L?>2.][:7: 'Y?O&V#\CZ><):/H&J>FIC1+$9EN8:GM8$4_<1?U0"IK M,KSB2JDM;=\FV24J)\T!7E 3',^!2M53CBOW1D 0+\H"?^Z!B@OX<\Q"*'Q! MI1B33"7D8>;*'..>%"LT83>+U!%MDE1#*57$^"[KI8"G>8@#026'Q4))/9^. M.F5?G3YQ]B?&:*Q&K9,<\Q)1D$Q$O+<>C=TFZ8RHP\/$R M8-&%)U7Z%*B_3WG,LLA\O(C@NU1'4+\*4')^IC+*@:VXF28O522XKJ-M^O]W M*>]IQ%CG=,TI866VE/.FYI.ER/\CA4O^7X54;17\OPL!'H%*R*/-$\+?X,-W^*7:Y'[S3IAZ[;8*K!(!ZQP43N MQ8&B';D7Y%ZL6$#G"4J]3$;*P3B#VZD0_*E_)9,HOF6_19ATK!+HF0BF>?.E MS?=9X$4!#F#76"8JX)]&11Z]\@2F&P5"68,U"9=[Z=*!'(5P*T[NS%F6YYBT M/)X[&Z!'*A.5*.9%ER',&7/^,7DLK06" U=T\,478L*\8JKB9H)&>*+B3^7G MZBPR2MXB^"5CLT+ 6P5C\S,?XVG!N*Z22\$V_(3IKY> L8"T&/%1IYARM-*I MKGB$.PH3.9"!/KRA_7 =)U?X^GYV9LEA?TX/K3G@H,-OQSI1ZYOP1B$"W*VC M+OH]@^'B?:(L]IZXMUHU ]&H*=QQU&!Q3JM.6LS*N-AQO((T#1GZU= W%3'T MO^B [;24T#5HFA?-NCL]>5'$>=-1+ 0;P]U&R;IC[8XV_F-]DG?E;1)0<0R4 MD(S\_.!U4^_FAEEAM4^+W>0Q#A&CGL(S_^AOX,;JC02U)8);UG&ZG3[SL[C8 M"=]LE,. @Q8=B7!NO.H<\.+MV\W%\=P[$YX'6/ XIG/ ;2E6: AZK M,+]S7&^^? )6PO7=EW?C]E;0LDM025!)4$E0N7NHG(OPE*O28-@Z3$3R0+B< MF::#6_:B,3/<':S7=?S26;*4=V%S/O\IM4.#4?/B% 2C!*/[R^[@05[O2%=" MPS#"(Q'4%V4$=1<0M-W8$$+9MY%,IC=3YN\DEC ZF!WS,Z%W3XM'B?$DB&X1 M^&NQ"%2KH>GP56FSF(-J@ *2P3E3R49UJ>+29^ M3LLBY7?4J47E5B5Y%8>U.Z83/+.<5W!^T>HU'S/_UG%S5QNE5=-N!)*4$4,9 M,?7LF?54I065SX%JXG^NTL:G/_2DH%.8A:*0@ M/ 7A*P.X=Z1]=%X^PN+K-.N]C:[+;5YOQ,-+,2LQ71K"4NB=ST+S\!-U#!WQ M(> #EF23"?Q0]6@8J9IDESKPOA1D@;O"X'!@%),GL*8H&R!1^K73X M=:-TD(? YO'BEEOO^=- ")8(E@B6J@1+#TD,> @Z->OM.71RNUM$IWESZCZ$ MFO\U+#[5?"D0ESR'+0>;.B4BQ8'/0J_<\Z(L3*>N=D7!;4M[X%6=TV\\P"JW M[&(D@,&'E[M@U)S63^$T0>=G!:KDA;MF''9)6'%&2J&3(X3FDL M585C_*K.+K)!(OZ9H>^4 PZ 5[&CG+?3GCXAWJ@S'/;=O:LI'.(-.(%>%L?X M6$"N*RRU!F32'8;K[&Q%GV>\$ M;ZBH;:F.^51K&$T[REHS$8D-\%>B6ZQS= M/\#-](&:AMLI._> MM@E^+U(N _.A]BY8FI51'$587AA7=S%A;._%!@ &H>K*SE/6.VDU&!^S\V\@ MTSZ_==@G%>]@E[7.;U\32^&I1PY+K,@B*Z3DSW0C[+2]]E M:[/Q++.J0NV?W:>Y_%<:TZA MGQ1;8L7![)D /&&>-,/[[S!#5L-E%D";?0 [[<1^KO:.CVOM!OYU>V9S!=L MQ+IO* \.@#/-AEOK]OJU7GO:6L!0SN2VX@'PY.EW. ND]X/]?O[UO$(F=87< MGO*@<6NYL,N5^<^#1/4"YE=@HZL0?Z2=U/,K50[]9]5P.&^=HLM@,C1OBWA# M[DI\C\8BG.TUY]7;/Q;-X;]B %-="P]/9"KJ[#1DZ$-@1#:_53&N6.#\ID7> MET:VM+.=WU,Y\-D$W>Y^@X&;DE3)JZZ00-WA1X-O.8BR]#ZQ\#;FS$);EP%/ MA!KD@]*S%HFSGA4;$VGJ1*^?(E,!?VS$64K+@/NH=@*W3CD)PLDC;..QB+'T MJ/P7+XZ)P+2*;BX.._U8FT37*D2GTYIQUT#Z16 I+P N5=1Q1>'O9"XBM@ER MSUS6S=BUO92ZG?#LH4OL'NDS=9K%*:*-=;-ZP .Z* $=3\\W%*!IAW=LPF'( MB%12TE#D05I=P%YR4$\\F1Y?V-E0+SYM-LPZ^Q9="EC7L8.K^Y:I_I6^;H@8 MA<&MBC3'8B1"U>MI$L7I, IDA*M_$$31&I 0J? *=%EH=EF$P-UZ\_],H]:G M $HPK9!=(]05((/%1;&H-E;:]D-QPP,VYDG"!/834(FZ7O$@4U9 O_]220L 6);7_(1;BB19'&J&6@7>>YGFW7YBB%T=?/Y\J ADTMW.82+AUBL7_7I'*GD![67BLI/;>'FYTBP&3)VR4Q51V(D M3;%KK2!7$7"!)]@D\VPDO!_/3SZ9S#HYUD"0YV5+B7.9G*JYA1S>EF8$N@TD M(IQZU6/H5/#41IXT$J9Q_"&+#K+LJ\!5SDY5*@]S^_U.G7U8>W^XYU44 ,SPTF%NQ'.=;YBALL$Q MXE,P"PD,^_6#S1.81/FC&&S_&"/1,!. HTL6*3A/1_!1XFCM*L>S?*/Q)!"% MH\+#VZ(F1E),?JK8RRI?J71UW]*3E7I%KZ_D=3?JTHY\R3S2D-;PBZ M/HHUXB;B+E)>ZF16=/A ZX,;DJ.8U$FI2 IPE[2U$/OHM. QFV3:QKJ$GK,> MS<67F%/JI@[ZH[8\)J MMN*9PPPY./MB1@#@%')@H>%C(58E<^FI4#BC1=ZX,E-+%-;O$2RUG MZ"MZ'!^A&*'E"%-C9HM"9X&E,L$+4I1>=VJ:I M#$#%1?R!7D!%8\'\3OG;XK)"YG+K5NH-Q'5K72TU6B[4.@HC8E%$OI9@0D%=O@)(A M@FF&4:KTH3HA4?Y=[HD%>$<8QU6.+7)3:)0 MWRX74KQHD9ME0N6VIIJ_PL1[&77J 9RC7@MNT=Q#@Q ?KD(4\V-2^?+YF.Z1 MT$?XH>2S6NJSKHRY+&_"XX]/9 HS\51NV%+NQ1DBI+=94M*B;-WOY&Z6"K14 M.@S,.W % )3 '/-^..S+J/[^,=)O)ZN7SB6,I!B66I3^.1Q*,-6)7O/T'F!D1/0C>!0Z;L6\)3\7Z[( M?#VJ@QNY":DZI03&RN=MA=A..BA[3-I3>U ]LLW83#[FLQV&V0F7'^A"/B!3 MMVQ:S"N@V2/[]8Y.]]M6HM]#Z/7T$GYW+)G^(XVP^R@%UI>/I_=]M,.2*)"^ MBNC-G>1.5@>$ELDU[:#8OHMV>4XXJ[47ELPFY-PNN>ZCSJO3,98E4*'6;^ T M)>#LXM:L]@CAU:T;CS&'&@^RAX H8!L#^YI']T 83/H0.)E[ M<;OFU2.. NH9E9,L[#9VGX&A4Y1D3]-,M*KL7%6D TD';I.3&*=C*FS)\BB> M*B&I/U)_M*"VMZ":I/GLY.UIDHC9T9J'K%I-^(U6[>I51WQ]-%_S MW;T/ZL\R4U_](^29+U/AOR9%N%?S=%MJ\A%L.?!%MA?*KXX<6TAYHU8$&1B/ MBO+OR)PH*YJS_*@_5U;$"2D;>T#-/L(;A6FT'H@M1K.%8(K6@T6FU]G9.<;[ MM\ KW5K-& L,V^RH\AWX L]P FO*U5*L ;GM<="<.,X2.U\\B6TF0N1JMCV M*$LG3X[@H=> @K\>Z7^/WC6=3O]8@QC)^GI97W%PATPI0AE"F5+=IFI]YY;"*J65;2J6["FJ@B1F A#0+AL%"H,FU8IB+&TBCP^H7; M4<;4B[Z#M38NQ"3-&A+[&88"^*N4[VNH:F-[=WQZRS M6I[?DSM83-J'-]:GB ]9+N92GG#"$)P #Z?=M-QZV=8VI%FV"Y8L"],HEL*P MS2P[3A)4$W5V1_LM;TDUK3)/=B&LUALGA!.$$_?A1,NU?4?)UM#*MRC%YI<[ MCZ(\\^F"@W:/C*3]=@&HXS1[#9M,E4..I!@IKX05MF"%VW5:C37;Q=;8*]8= MTOH21Q,1Y_U:,4-8=;/1^2]F!59,XE[U ,@\PF\;?=;L0I.D5LM*L8_NA!!& M($2KV[/<.-FBA6V*>?(51U"+AC75>'"CD=$P,EV\FY(A_(/.IO.^?-)KN$HB7&B2N!A3U@X79; MEMLH=I[>T>FQ.S-3GI!M!51B?I1A/^@*I^7O@86[*!-E)-^VBUA=I]E=$^>M MIH5SN)$7(Z654(90!NRB8Z=U;+MI]/SF_8X6P)T]F?Z0?" #FS&4GDQ?L_-_9C+==M6Y.Y;! 7'_F9P[>XEO5''S M:EICQ!@"+ *L@UP7UMAUUJ4)%8VP@IGI1MVP+ $W.PE?C0 ,T9WH3D!3:<+O M5^"M,9%L+9LS;<4PX;?8A\&^(^C/[P56-&IO(MNV'+1WFEU*?C),91#E"66L M0IE>S_:T;CM3IL TBC/AEX-(]EE'Y-L91/@M'R=Q>NN2-4E6R;8AC"",>-=R MV@W;#\';&KHI-KDF49S**,2&F4$47M9@78V9+P:I=<;*\SM9!PM%^SE;LJ;X M.DDK&2S/3WG""4-PHMVP/=':SH#*Q0@L%8O-$_*3#"+\E@^1'5O5E($B*?;0 MG1#""(0X[K8M-TILC:/$7@BIKL\VSZY]42^45T.JLNQ4>RDLZ813#45)<5. MC)-70@M[T.)X33=<:VP5.P,H\STN=YR7\LP-U [853*0\MN%GX[CNE:9*X<; M3S%05@DE;$&)3M-V.\7"@LB?H["VPD2Q[_PUN4F6D;X:&IDQ M1O&-@,? K>[VNA@R22N9)\]/><()0W"B>6S[.6@[ R??>1SS^:TFLTR4[62% MD7-D%NVW'4/IKNO]6TUE23$4HZ25D,(6I&@ZS=Z::*LUAHJMD12=OFMPVBX= M'WC6K+SJG!_H.5T*J]ABL9@JLH08%B&&VW!:?=M/2-O71RD:CV4Z%M@@ %M? M>O #F(P(O=V$60S,:2<4JBKEJZ%]+4&LRM'=0H$GJ#D,D;?&7K+P]-/JYN!^ MT1Q:(\P8T%I"<#ZLFV;,>M-QI5-Y\PX!2%<"NP MHAPVX3'R)!/L!8RSX;*)B%DRXK%P6+/1_63A %U1E$,=_<9 M3]E[X8GQ &[0B>#V#4S7Z;8[3J/=5Q?U MG%:CZ[2:W>)),DFP4Q1^%V5IDL(+8,'3GFJ=C;@U827(?CKAMQS=MS9Y:5N" M2E8= <0! T3/\IT_6U.63F$"V%R*!V",2;\F0^;QB<0$NOL$W(J#2/]=B&H MXW:,LX*GP6;[O9IBM0N<\Z)S' M?0CTJN-BE+'UV@!Y-0AJ#LI.(9P@G+@?)QJNTW67<<(:*\76T(H^#99LDB]D M6*8U'?J@0Q^;@5/3:74[EI@PAQQL,55<"2TL0HNNTS]>TQ7&&F/&SI#+\L%V M3'*IH&D#1&5^E T"466/:P\D2"I#P(]4K1S]+"T3^)[ERRKG\G$;;6H8>"&=3[A7>YZC^+.C M=_?0:[HH-B+7')7"*![S8,6*OT\S;":@RBK-*3P_KF).\*M?C]RC=^4=N;>C M./^B-5W!>K'\U%=_CIA:T'!AH_'RB.5K7H\(7H )O#$-=2\2[U1-4,QO5<;7.M1#\!3>)/S7:-KZ9']?,F=)A,9<_8]&HNP\"D2]KO@03IB M'T.OOHM5<:>I]=0ET]\,)A],J;,(02@1/H-72NFI'?&+%/[1!3VB(?MS(F*. M^7W34F0;H2_^;=]%Q1P 6:W=6&E@W$G8[1+N/CJ].AV#>@9RR)!]&T59 JYK MXK#S&T_ R"[P?(?R9K_PF/V/.HN27_#Z,:+V$*AXFN9<@W%OE=9GG@B"7!/] M>M0X4N^3"?>*]_F5.9^ A@&?).*D>/%&WQ+4,)[+>;FDY8KA;QZL:?7-"]8L M!+UV?;QJ_CE3UV;)LV'NPZQM;3NJX2X(S"/]H6:]TR56;<*J+0:&&_5CPS/Q M[",Z23H1_3"(CO!"1"=))Z(3T0E>[" Z23H1_3"(#O#2[1'1MTGT1V7#],N94J-8"/8)/AXE[#ST MA6]=*&Z_"VY;&2"TDBJVDOY7\/C>%62G%FO5.[LU)@Y&B^W@E-=3F%.AY5>N M:V>W"MOY:JN^"J-EM.-E1'JL4GJL^:@%^/RG? YQ!6)-UATH,).:7#P#)[>N MTVA)56I)-'JP.A MO16KPAJX,IW0]BP!N%23I6(D6ZP!&^..YN\>;(Z=_O$:2\6: M8,T6^W*9%*[YNPA%*KW$K'B-<4UTS%$"6P^\F$'K5KW9F:V0E;ACRI)AFGTU MLY:,41!'1I9IZ\M8+*L,K;=L,EGEG%DIG80$A 1[0 *7@(!," (.4VHA5@\##OAM8/3EM9 S)8/=.V.U)3N0IM(!!R&D'K[IQTJ M!!RT^VRX=!(0$!#L)0UEC9=RX$! %@0!QS,<,:H*,/"ZC5G49)B MI]V8JMA4#&<.I6;- W))JKE98"SE#][,,8LSYE#Z@*I"$/H7J5AVJ 59W.ZQY2$@2PNR>/.GE@P[M$2G(ZDP"V6S'*2)8J8L6P ; M52'UMF&#BK*8+9L$ P0#E-U"]@,!A]' <:!%60 XNFL<#VM"'!869?E['"4) MF\314.[BA(X]A]N,PIBJ%&39<@S5:;I]FVP3VH AX*BT5U,=X&A;5:O:2O$D M(" @V#$0=)QFUZKH!ED0!!R5#F]4!#C:3JNY9G_$FNB&=0D:0N2K%# AU*D1W(O.!D9E0 MA,2;;)?#8(LY9*Y*795JH8XU@1U+B[-\%8G@L3=B//29+ZY$$$W&(K2OT*RM MH63CHCS[V8MN'*\Y"GCPTDF&CJ&,,8?0)CI8>X*-!NU6]]E^J/5##&<<$#^ $&.&"L/P0FLU@7WK S(&M< M<&/W1P!=Y[A-103(-*D,6\PALXG^S.X!H^GT>CT"#*,ED\A, + S #AV>JY5 M44VR&.QFBSED-C&4L0<7H^WTW34!4&LB&9;F:V SG9@'*IK!_;$,99+B^9RK M7115?0('J8"S'>UUMNVK=%IKNGA54R?2S@N!1[5=G"J!1[MM555F*P64P(# M8!^I7$VGN:X;Q,&C 9D2A![42.;N"$BWN:8*HC41D+E 4JO>:>Q49/<0^]"] M9**E@B3,L)JK.Z@VO'/V5;3HZNY(O>W"9MMQ73(AR(0@Y#"DZFI5D*/5<=K45:9ZX8X_ ML*G,,([&1<@C"HT+=520CMX0:U@0V M[&LHDXY$#%=ZT5BP5WD.QVN'A2*ESC+5@)I*E.6H5IWD Q=OVVP<2]AB#IFK M>DQTK:K):J5L$J$)!'8* FMK#!R\;)+E8"ACS"&TB5&3_32I.VZL M.>=G3SEVL\4<,IOH MRNP!+*RJM&BA6!*9:?7O+I9I52B3; 6[V6(.F4V,8.RANXSM/7(MS=?X$,$( MKT0HD@33--Z?G[UG0<1#ZT(8MD9+C0MB/)70K7JS,ULK*^''E,7#-.]JM%C( M7JH<8\PAM(G^%:$8+18C%PL1FE!IQSO1C4;#IM /&3/V,\8<0IL8_B%CQLJ0 MU+;J-1L5D+JC4(Q9!BK5W-Y74*HJ);?=GKWI-52IWW!1M@ T*D+I[8)&AR## M:,$D"" (V#$$M'L$ F0W$&@8$6ZI"FB\:G:XCC^9M= M;8^99@&/D5V-5Q-[ZUM$[:Y-)LL6)=0VH\54B;8 /JI#["V'/*S>7[9#/@D, M" SV @9-Q[6ZTAK9$N9+=/7AP\@FQ_MQ19J=EN5'C_8;MMM#&.2S2%F ?8[- M"GO$D+FT]3K([+FTY0-MR&KV^)8T-:4^'X*8R<%,1 M+FU[/\CI6---V<*-2H(/@@^3X/.H0BIA&;4,1D%''K/5O" MQ&2[$.I4"G468CTF,VK;F^%UFX,]Y7A9\[C>J'Q4\[L:@O 9!PCCEX)YT7@< MA3KJD[ L@:_2"#^=9*E8$00*R[&B\L5VAH?V*P#/=,#)7%)O.:>PX;0;/<=M M6967_"01G9?+1N/E,AW) #H4@IOJ/NT>&7I.L]]WCNUJ\&JMG!(P$##L"1CZ M3K/5-NWW$;:RR&:00$7G"8#+C%OKS2 MGZSS%-TE9F\2*'"G@8([HP1'[W[^Z>8#QH-R/UT/;I(/Z5U^,=SSUR/WZ%W9 MFW\[BO,O6E/V:T+_U%=_CIB2!K@0I/.(Y0+C"0RM'L$M1HH4F@)O?QE$_BV\ MAX_3+:K%NH" !"@ $ M @ $ 87=H+3(P,C0P,S(X+GAS9%!+ 0(4 Q0 ( $V&?%AT>+46 M\04 %<] 4 " 1@# !A=V@M,C R-# S,CA?;&%B+GAM M;%!+ 0(4 Q0 ( $V&?%BWX(P>JP0 /$K 4 " 3L) M !A=V@M,C R-# S,CA?<')E+GAM;%!+ 0(4 Q0 ( $V&?%@Z^8\R314 M &0@ 0 3 " 1@. !A=V@M,C R-# S,CAX.&LN:'1M4$L! M A0#% @ 389\6!8G[<#-+0 (-L# !< ( !EB, &%W K:"TR,#(T,#,R.'AE>#DY7S$N:'1M4$L%!@ % 4 2 $ )A1 $! end XML 18 awh-20240328x8k_htm.xml IDEA: XBRL DOCUMENT 0000926617 2024-03-28 2024-03-28 false 0000926617 8-K 2024-03-28 Aspira Women’s Health Inc. DE 001-34810 33-0595156 12117 Bee Caves Road Building III Suite 100 Austin TX 78738 512 519-0400 false false false false Common Stock, par value $0.001 per share AWH NASDAQ false